You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Around the Region

Cubist seeks therapies to fuel growth

NEW YORK ­— Cubist Pharmaceuticals Inc., maker of the antibiotic Cubicin, is seeking early-stage experimental therapies to buy or license to fuel growth beyond the next five years, chief executive Michael Bonney said.

Cubist expects to reach $2 billion in annual revenue, earn $700 million in profit, and have four products in late-stage clinical trials by the end of 2017, the Lexington, Mass.-based biotechnology company told investors Monday at a presentation in New York.

Continue reading below

Cubist’s focus is acute care products used in hospitals to treat bacterial infections or aid with recovery from surgery. The company had $861.7 million in cash and equivalents as of March 31.

It has made two acquisitions since 2009, both of companies with therapies in later stages of development. The focus now is to find products to follow those, Bonney said.

“We need to be feeding that so that when we get to 2017 we have replacement stock coming” to follow the later-stage products, Bonney said.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.